Clinical trial · Interventional
Monitoring and Mapping of Erectile Nerve During RALP (MMEN Study)
Safety and Efficacy of Pelvic Autonomic Nerve Monitoring and Mapping During Robot Assisted Laparoscopic Radical Prostatectomy for Preservation of Erectile Function
NCT02507427CI-TRIAL-00037072completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the safety and efficacy of pelvic autonomic nerve monitoring and mapping during robot assisted laparoscopic radical prostatectomy for preservation of erectile function.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NIM-Eclipse | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Nerve monitoring arm
- description
- They will receive pelvic autonomic nerve monitoring and mapping using NIM-Eclipse (Medtronic) during robot-assisted laparoscopic prostatectomy.
- interventionNames
- Device: NIM-Eclipse
Primary outcomes (1)
- measure
- Completion rate of nerve monitoring and mapping during RALP
- timeFrame
- During the operation
- description
- Completion rate of planed surgery without significant intra-operative complication
Secondary outcomes (4)
- measure
- Adverse event
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 19 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * pathologically proven localized prostate cancer (≤cT3a) * patients to undergo robot-assisted laparoscopic prostatectomy at our center Exclusion Criteria: * prior hormone therapy * prior radiation treatment on prostate or pelvis * refused to participate
References
Publications (0)
Data not yet available
No reference posted for this study.